Cavanaugh Sarah 4
4 · Celldex Therapeutics, Inc. · Filed Jun 3, 2024
Insider Transaction Report
Form 4
Cavanaugh Sarah
SVP OF CORP AFFAIRS & ADMIN.
Transactions
- Exercise/Conversion
Common Stock
2024-05-30$2.78/sh+10,750$29,885→ 12,610 total - Exercise/Conversion
Common Stock
2024-05-30$9.02/sh+10,103$91,094→ 22,713 total - Sale
Common Stock
2024-05-30$33.73/sh−20,853$703,334→ 1,860 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2024-05-30−10,750→ 0 totalExercise: $2.78Exp: 2029-06-19→ Common Stock (10,750 underlying) - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2024-05-30−10,103→ 0 totalExercise: $9.02Exp: 2028-06-13→ Common Stock (10,103 underlying)
Footnotes (4)
- [F1]Includes 576 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.465 to $34.06 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]As of June 19, 2023, the option is fully vested.
- [F4]As of June 13, 2022, the option is fully vested.